Topic - Ugur Sahin

Related Stories

Vaccine maker BioNTech says no need to waive patents

By FRANK JORDANS - Associated Press

In this Thursday, March 18, 2021, file photo, Ugur Sahin, co-founder of the Mainz-based coronavirus vaccine developer BioNTech, listens during an Axel Springer Award ceremony. Europe can achieve "herd immunity" against the coronavirus within the next four months, the head of German pharmaceutical company BioNTech, which developed the first widely approved COVID-19 vaccine with U.S. partner Pfizer, said Wednesday. (Bernd von Jutrczenka/dpa via AP, Pool, file)

BioNTech chief: Europe will reach herd immunity by August

By Frank Jordans - Associated Press

File -- In this Tuesday, Nov.10, 2020 file photo windows are illuminated at the headquarters of the German biotechnology company BioNTech in Mainz, Germany. German company BioNTech was little-known outside the pharmaceutical industry before it teamed up with U.S. giant Pfizer for “Project Lightspeed” that beat major rivals in the race to put the first thoroughly vetted vaccine on the market. (AP Photo/Michael Probst, file)

Vaccine maker recounts ‘breakfast table’ pivot to COVID work

By FRANK JORDANS - Associated Press

File -- In this Tuesday, Nov.10, 2020 file photo windows are illuminated at the headquarters of the German biotechnology company BioNTech in Mainz, Germany. Pfizer and BioNTech say they've won permission Wednesday, Dec. 2, 2020, for emergency use of their COVID-19 vaccine in Britain, the world's first coronavirus shot that's backed by rigorous science -- and a major step toward eventually ending the pandemic.(AP Photo/Michael Probst, file)

Vaccine 1st puts spotlight on German pharma company BioNTech

By DAVID McHUGH and FRANK JORDANS - Associated Press

This handout photo taken in October 2020 and provided by Pfizer shows part of a &quot;freezer farm,&quot; a football field-sized facility for storing finished COVID-19 vaccines, in Puurs, Belgium. Pfizer's experimental vaccine requires ultra-cold storage and are being stored in special freezers until approval and distribution. Pfizer Inc. said Monday, Nov. 9, 2020, that its COVID-19 vaccine may be a remarkable 90% effective, based on early and incomplete test results that nevertheless brought a big burst of optimism to a world desperate for the means to finally bring the catastrophic outbreak under control. (Pfizer via AP)

BioNTech scientist: Vaccine could halve virus transmission

Associated Press